M&A · Healthcare · In Vitro & In Vivo Diagnostic Substances
Curium US Holdings LLC to acquire Lantheus Holdings, Inc.
Announced Aug 3, 2026 · Pending Aug 26, 2026
Deal value$6.67BEV $6.75B
Premium9.0%To unaffected price
EV / Adj. EBITDA14.6x4.4x EV / Revenue
ConsiderationAll cash$102.50 per share
Transaction
- Acquirer
- Curium US Holdings LLC
- Target
- Lantheus Holdings, Inc. (LNTH)
- Buyer type
- Strategic
- Offer price per share
- $102.50
- Enterprise value
- $6.75B
- Status
- Pending Aug 26, 2026
Deal protections
- Break fee (target pays)
- $228M · 3.4%
- Reverse fee (buyer pays)
- $385M · 5.8%
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Jefferies, JPMorgan, PJT Partners
- To the target
- Morgan Stanley, BofA Securities, Solomon Partners
Sector context · Healthcare
- Comparable deals
- 108 in the prior 24 months
- Premium
- 9.0% vs. 46.0% sector median
- EV / Adj. EBITDA
- 14.6x vs. 10.7x sector median
- Break fee
- 3.4% vs. 3.5% sector median
Timeline
- AnnouncedAug 3, 2026
- Proxy filedAug 26, 2026
- Definitive proxySep 8, 2026
- Shareholder votePending
- ClosedPending
Valuation · fairness opinions
Discounted cash flow$88.10$118.60
Trading comparables$63.85$84.20
Premiums paid$119.05$134.15
Premiums paid$113.45$131.15
Premiums paid$105.85$124.05
Offer $102.50
Implied value per Lantheus Holdings, Inc. share by analysis, from Morgan Stanley · DCF discount rate 8.8%–10.7%.